Appeals court restricts mailing of abortion pill mifepristone
A federal appeals court has ruled against the mailing of mifepristone, a medication used for abortion. This decision alters how the medication can be accessed in the U.S. (sources: cbsnews, npr, pbs, abcnews, cnn)

The 5th U.S. Circuit Court of Appeals has mandated that mifepristone can only be distributed in-person at clinics, impacting access to this abortion method.
- The 5th U.S. Circuit Court of Appeals issued a ruling blocking the mailing of mifepristone.
- The ruling requires that mifepristone be distributed only in-person at clinics.
- Mifepristone is one of the most commonly used medications for abortion in the U.S.
Why it matters
This ruling may significantly affect access to abortion services across the United States.
↓ Why this is on ModernAction
5 bills on this issue are moving right now — and the most active one is Protecting Life from Chemical Abortions Act.
HR1525 · 119th Congress
Protecting Life from Chemical Abortions Act
Where do you stand on this bill?
Takes about 60 seconds
About this bill
What HR1525 actually does
This story is about a court decision that restricts mailing access to mifepristone and changes how the medication is accessed. This bill would nullify recent FDA changes to mifepristone dispensing rules and restore stricter in-person dispensing requirements.
If passed, it would:
- Restore pre-change REMS in-person dispensing rules for mifepristone • Remove or block FDA modifications that allowed wider dispensing (including mail.
4 other bills moving on this issue
Take action on any of them individually.
This story is about Appeals court blocks mailing of abortion pill mifepristone in U.S. This bill would revise federal criminal/shipping provisions commonly referred to as the Comstock Act and related statutes.
If passed, it would
- Revise federal criminal/shipping provisions commonly referred to as the Comstock Act and related statutes • Reduce legal leverage for treating the mailing/shipping of abortion drugs/devices as categorically unlawful under.
This story is about Appeals court blocks mailing of abortion pill mifepristone in U.S. This bill would require an in-person physical exam and provider physical presence for “chemical abortions.
If passed, it would
- Require an in-person physical exam and provider physical presence for “chemical abortions • Create criminal penalties for providers who do not comply (while barring prosecution of the patient.
This story is about a court blocking mailing of the abortion drug and shifting access to mifepristone. The bill would direct HHS to return the mifepristone REMS to the 2011 version and add a federal ban on importation or mailing of mifepristone.
If passed, it would
- Require HHS to reinstate the 2011 mifepristone REMS • Add a federal prohibition on importation or mailing of mifepristone.
This story is about limits on access to an FDA-approved abortion medication after a court restricted mailing. The bill would bar enforcement of laws that restrict sale or provision of FDA-approved medicines and create a private right of action to challenge such enforcement.
If passed, it would
- Prohibit enforcement that restricts sale or use of FDA-approved medicines • Create private legal remedies and injunctive relief against enforcement.
Top coverage · 6 sources
